GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B7729 DR 4485 hydrochlorideSummary: 5-HT7 antagonist -
B7730 TC-G 1000Summary: α2D-adrenoceptor agonist -
B7735 AS 2034178Summary: GPR40 agonist -
B7752 GSK 1562590 hydrochlorideSummary: urotensin II (UT) receptor antagonist -
B7765 ML 154Summary: neuropeptide S receptor (NPSR) antagonist -
B7768 NBOH-2C-CN hydrochlorideSummary: 5-HT2A agonist -
B5002 L-693,403 maleateSummary: High affinity σ ligand -
B5007 IPAGSummary: Potent σ-receptor antagonist -
B5009 MetaphitSummary: Acylator of PCP and σ-receptors -
B5018 SB 203186 hydrochlorideSummary: Potent 5-HT4 receptor antagonist
